[johnforbes]

Global HCQ studies. PrEP, PEP, and early treatment studies show efficacy, while late treatment shows mixed results.
8/21

Positive Early Ly et al., Preprint, 2020 (Preprint) Pattern of SARS-CoV-2 infection among dependant elderly residents living in retirement homes in Marseille, France, March-June 2020

Retrospective analysis of retirement homes showing HCQ+AZ >= 3 days resulted in 41% lower mortality (15.5% vs. 26.4%), OR = 0.39, p=0.026. 1690 elderly residents (mean age 83), 226 infected residents, 116 treated wi..

8/21
Safety N/A Lane et al., The Lancet Rheumatology, doi:10.1016/S2665-9913(20)30276-9. (Peer Reviewed) (not included in the study count) Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study

Retrospective study of RA patients using HCQ vs. sulfasalazine (another DMARD). HCQ treatment showed no increased risk in the short term (up to 30 days) among patients with RA. Long term use w..
8/21
Positive Late Gonzalez et al., medRxiv, doi:10.1101/2020.08.18.20172874 (Preprint) The Prognostic Value of Eosinophil Recovery in COVID-19: A Multicentre, Retrospective Cohort Study on Patients Hospitalised in Spanish Hospitals
Retrospective study focused on eosinophil recovery with 9,644 hospitalized patients in Spain, showing lower mortality for HCQ (14.7% vs 29.2%, p<0.001), and AZ (15.3% vs. 18.4%, p<0.001). With a multivariate model i..

8/20
Positive Late Dubernet et al., J. Global Antimicrobial Resistance, doi:10.1016/j.jgar.2020.08.001 (Peer Reviewed) A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: results of a retrospective observational study in the French overseas department of Reunion Island
Retrospective analysis of 36 hospitalized patients showing HCQ/AZ associated with lower ICU admission, p=0.008. Median age 66, no mortality. Confounding by indication, however it was patients with hypoxemic pneumoni..
8/20

Safety Early Prodromos, C., New Microbes and New Infections, doi:10.1016/j.nmni.2020.100747 (Peer Reviewed) (not included in the study count) Hydroxychloroquine is protective to the heart, not Harmful: A systematic review
Review concluding that HCQ/AZ does not cause Torsade de Pointes or related deaths, HCQ decreases cardiac events, and HCQ should not be restricted in use for COVID-19 pat..

8/17
Safety Early Mohana et al., medRxiv, doi:10.1101/2020.08.16.20175752 (Preprint) (not included in the study count) Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia
Safety study of 2,733 patients in Saudi Arabia showing HCQ in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and has ..


8/15
Negative Late Peters et al., medRxiv, doi:10.1101/2020.08.14.20173369 (Preprint) Outcomes of Persons With COVID-19 in Hospitals With and Without Standard Treatment With (Hydroxy)chloroquine
Retrospective study of HCQ use in 9 hospitals in the Netherlands, showing no significant difference in mortality with HCQ/CQ or dexamethasone. Late stage (admitted to ho..

8/14
Inconc. Late Abd-Elsalam et al., American Journal of Tropical Medicine and Hygiene, 10.4269/ajtmh.20-0873 (Peer Reviewed) Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study
Small RCT in Egypt with 97/97 HCQ/control patients. @28 days, 58% more HCQ patients recovered (53.6% HCQ, 3